<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82447">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02032004</url>
  </required_header>
  <id_info>
    <org_study_id>MSB-MPC-CHF001</org_study_id>
    <nct_id>NCT02032004</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.</brief_title>
  <acronym>DREAM HF-1</acronym>
  <official_title>Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mesoblast, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mesoblast, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether transendocardial delivery of
      allogeneic human bone marrow-derived MPCs (rexlemestrocel-L) is effective in the treatment
      of chronic heart failure due to LV systolic dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of a single
      transendocardial delivery in the cardiac catheterization laboratory of human bone
      marrow-derived allogeneic MPCs (rexlemestrocel-L) for improvement in clinical outcomes
      (HF-MACE), preventing further adverse cardiac remodeling (LVESV and LVEDV), and increasing
      exercise capacity (6MWT) in patients with chronic HF due to LV systolic dysfunction of
      either ischemic or nonischemic etiology who have received optimal medical/revascularization
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to non-fatal recurrent first decompensated heart failure (HF) events in the presence of terminal HF-related major adverse cardiac events (HF-MACE)</measure>
    <time_frame>12 Month minimum</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total hospital admissions for non-fatal recurrent decompensated HF events</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospital admissions or urgent HF visits for non-fatal decompensated HF</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of in-hospital stay in intensive care unit for decompensated HF</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-fatal recurrent decompensated HF events resulting in hospitalization or urgent HF visits</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac survival (captures only cardiac deaths)</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (captures all cause deaths)</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-first HF-MACE</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-death from cardiovascular causes</measure>
    <time_frame>12 Month minimum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular remodeling in LVESV determined by 2-D echocardiography</measure>
    <time_frame>Baseline, months 3, 6, 12 and every 12 months thereafter until study conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV remodeling in LVEDV determined by 2-D echocardiography</measure>
    <time_frame>Baseline, months 3, 6, 12 and every 12 months thereafter until study conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Left Ventricular systolic performance performance as assessed by LVEF (RVG or echocardiogram)</measure>
    <time_frame>Baseline, months 3, 6, 12 and every 12 months thereafter until study conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional exercise capacity as assessed by 6 Minute Walk Test</measure>
    <time_frame>Baseline, months 3, 6, 12 and every 12 months thereafter until study conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional status by New York Heart Association (NYHA) class</measure>
    <time_frame>Baseline, months 3, 6, 12 and every 12 months thereafter until study conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measure - Minnesota Living With Heart Failure (MLHF) questionnaire</measure>
    <time_frame>Baseline and months 3, 6, 12 and every 12 months thereafter until study conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measure - EuroQoL 5-dimensional (EQ-5D) questionnaire</measure>
    <time_frame>Baseline, months 3, 6, 12 and every 12 months thereafter until study conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-terminal HF-MACE</measure>
    <time_frame>Minimum 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of rexlemestrocel-L will be assessed throughout the study</measure>
    <time_frame>Minimum 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics Studies Measures</measure>
    <time_frame>Baseline, months 3, 6, 12 and every 12 months thereafter until study conclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenomics (PGx) Analysis</measure>
    <time_frame>Screening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Measures</measure>
    <time_frame>Screening, day 10, months 1, 3, 6, and 12, and every 6 months during study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory Measures</measure>
    <time_frame>Protocol specified time points during the course of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Allogeneic Mesenchymal Precursor Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomly assigned to treatment will undergo a single index cardiac catheterization involving transendocardial delivery of rexlemestrocel-L into the myocardium at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Participants randomly assigned to control treatment will undergo a single cardiac catheterization involving a scripted sham cardiac mapping and cell delivery procedure at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic Mesenchymal Precursor Cells (MPC)</intervention_name>
    <description>Rexlemestrolcel-L consists of human bone marrow-derived allogeneic MPCs isolated from bone mononuclear cells with anti-STRO-3 antibodies, expanded ex vivo,and cryopreserved</description>
    <arm_group_label>Allogeneic Mesenchymal Precursor Cells</arm_group_label>
    <other_name>MPC</other_name>
    <other_name>rexlemestrocel-L</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Comparator</intervention_name>
    <description>The sham procedure will be staged to script and will not include actual cardiac mapping or delivery of rexlemestrocel-L.</description>
    <arm_group_label>Control Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is 18 to 80 years of age, inclusive; both men and women will be enrolled.

          -  The patient has a diagnosis of chronic HF of ischemic or nonischemic etiology for at
             least 6 months

          -  The patient is on stable, optimally tolerated dosages of HF therapies including
             beta-blockers (approved for country-specific usage), angiotensin-converting enzyme
             (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and/or aldosterone
             antagonists, without change in dose for at least 1 month before study intervention

          -  The patient is on a stable, outpatient, oral diuretic dosing regimen in which the
             patient remains clinically stable during screening.

          -  Other Criteria apply, please contact the investigator

        Exclusion Criteria:

          -  The patient has NYHA Functional Class I or Functional Class IV symptoms.

          -  Other Criteria apply, please contact the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donna Skerrett, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mesoblast, Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>inVentiv Health</last_name>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aimee M Barrera</last_name>
    <phone>+1 919 602 5311</phone>
    <email>mailto:aimee.barrera@inventivhealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10757</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13262</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10779</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10756</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13023</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10786</name>
      <address>
        <city>Mesa</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13276</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10754</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10759</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10775</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13265</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10778</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13031</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13275</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13267</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10780</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10760</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13273</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10768</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13270</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13264</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13027</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10765</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10772</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13030</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10783</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13022</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13266</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10782</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10766</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10762</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10761</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13263</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10776</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13026</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10781</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10758</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10770</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10773</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10785</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10767</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13261</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13277</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10774</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10777</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13024</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13028</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13274</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10755</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 13268</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10763</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10771</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10764</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10769</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 10789</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 11026</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 11025</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mesoblast Investigational Site 11024</name>
      <address>
        <city>Victoria</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimee Barrera</last_name>
      <email>aimee.barrera@inventivhealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Belarus</country>
    <country>Bulgaria</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 27, 2016</lastchanged_date>
  <firstreceived_date>January 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Heart Failure</keyword>
  <keyword>CHF</keyword>
  <keyword>Left Ventricular Systolic Dysfunction</keyword>
  <keyword>Ischemic Heart Failure</keyword>
  <keyword>Nonischemic Heart Failure</keyword>
  <keyword>Stem Cells</keyword>
  <keyword>Allogeneic Mesenchymal Precursor Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
